LOS ANGELES, CA – (GLOBE NEWSWIRE – December 3, 2018) — Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it will be presenting at the 11th Annual LD Micro Main Event in Los Angeles. See www.ldmicro.com/events.
The corporate presentation is on Wednesday, December 5, 2018 at 12:00 PM Pacific/3:00 PM Eastern. Mr. Robert Brooke, CEO of Vitality, will be giving the presentation and meeting with investors during the event. There will be a live webcast of Vitality’s presentation at: http://wsw.com/webcast/ldmicro15/vbio/.
The event marks Vitality’s first corporate presentation since the completion of a recent $8.5 million financing that will support company operations into at least 2020. Mr. Brooke will discuss clinical development plans for VBX-100, the Company’s proprietary THC pharmaceutical that is designed to provide therapeutic effects without any psychoactivity, as well as the launch of Vitality Healthtech, a wholly-owned operating subsidiary focused on combatting the opioid epidemic.
About Vitality Biopharma (Ticker: VBIO)
Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. The Company’s operations include federally-compliant cannabinoid drug development and the launch of a specialty care treatment network in the United States focused on the reduction of opioid dependence. For more information, visit: www.vitality.bio. Follow us on Facebook, Twitter and LinkedIn.
Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.